Abatacept
Severe
Database
Drug interaction classified as: synergy.
Source: DDInter
Drug reference
Etanercept
TNF-alpha inhibitor (soluble receptor fusion protein) · Immunomodulator, Anti-rheumatic, Anti-psoriatic
Also known as Enbrel, TNF-alpha fusion protein
START
50 mg SC once weekly (after TB/HBV screen)
TYPICAL MAX
50 mg/week (100 mg/week initial psoriasis only)
STOP IF
Serious infection, demyelination, or new malignancy
WATCH
Latent TB/HBV screen, infection signs, CBC, neuro symptoms
CDSCO approvedSchedule HATC L04AB01
KDIGO 2024 + manufacturer label
- ONSET
- 12h · SC absorption
- PEAK
- 2.5d · serum Cmax
- t½
- 3.5d · t½ ~3.5 d
- DURATION
- 1w · weekly
EXCRETION
Proteolytic catabolism; not excreted intact
route + CYP
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Limited data; use only if clearly needed (low third-trimester transfer vs IgG1 mAbs).
FDA category + note
Top interactionssee all 12 →
- AbataceptSevereDatabaseDDInter
- AbemaciclibSevereDatabaseDDInter
- AcalabrutinibSevereDatabaseDDInter
- AdalimumabSevereDatabaseDDInter
Available in India
5 branded formulations. Look up specific brands in the Drugs workspace.
Mechanism
Recombinant human TNF-receptor p75–Fc fusion protein that competitively binds soluble and membrane TNF-alpha (and lymphotoxin-alpha), neutralising TNF-driven inflammatory cascades in immune-mediated disease.
Indications
Rheumatoid arthritisPolyarticular juvenile idiopathic arthritisPsoriatic arthritisAnkylosing spondylitisPlaque psoriasis
Dosing
- Adult
- 50 mg SC once weekly (or 25 mg SC twice weekly); psoriasis may start 50 mg twice weekly for 12 weeks.
- Pediatric
- JIA (≥2 y): 0.8 mg/kg SC weekly (max 50 mg/week).
- Renal adjustment
- No dose adjustment required.
- Hepatic adjustment
- No specific adjustment; screen/monitor hepatitis B.
- Geriatric
- No dose change; greater infection risk — monitor.
- Max dose
- 50 mg/week maintenance (100 mg/week initial psoriasis)
Pharmacokinetics
Onset
Clinical improvement over 1–4 weeks
Peak effect
~48–72 h serum (SC); clinical weeks
Duration
~1 week (weekly dosing)
Half-life
~70–100 h (~3–4 days)
Bioavailability
~60% (subcutaneous)
Protein binding
Not applicable (fusion protein)
Metabolism
Proteolytic catabolism to peptides/amino acids
Excretion
Catabolised (not renally/hepatically excreted intact)
Contraindications
- Active serious infection / sepsis
- Hypersensitivity to etanercept
- Moderate–severe heart failure (NYHA III–IV) — caution/avoid
Side effects
Common
Injection-site reactionsUpper respiratory infectionsHeadacheRash
Serious
- Serious infections / sepsis
- Reactivation of tuberculosis / hepatitis B
- Demyelinating disease
- Lymphoma/malignancy (boxed)
- Pancytopenia/aplastic anaemia
- Worsening heart failure
Pregnancy & lactation
Pregnancy
Limited data; use only if clearly needed (low third-trimester transfer vs IgG1 mAbs).
Lactation
Minimal milk transfer; generally considered compatible.
Drug interactions
Abemaciclib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Acalabrutinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Adalimumab
Severe
Database
Drug interaction classified as: synergy.
Source: DDInter
Aflibercept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Aldesleukin
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Altretamine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Anakinra
Severe
Database
Additive immunosuppression
Do not combine biologic DMARDs
Source: Kimi deep-research + Cla
Antithymocyte Immunoglobulin (rabbit)
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Asparaginase Escherichia Coli
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Atezolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Avapritinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Related guidelines
Ask House about Etanercept
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20